Factors Predicting Recurrence in Thymic Epithelial Neoplasms

• Published in: European journal of cardio-thoracic surgery 2022-10, Vol.62 (5)
• Main Authors: Alkaaki, Aroub, Abo Al-Saud, Ali, Di Lena, Élise, Ramirez-GarciaLuna, Jose Luis, Spicer, Jonathan, Ferri, Lorenzo, Mulder, David, Sirois, Christian, Cools-Lartigue, Jonathan
• Format: Article
• Language: English
• ISSN: 1010-7940; 1873-734X
• DOI: 10.1093/ejcts/ezac274

Thymic epithelial neoplasms (TEN) represent a heterogeneous group of rare thoracic malignancies. We analyzed the clinicopathological features, survival outcomes, risk factors, and patterns of recurrence in patients undergoing resection. Records were reviewed for adult patients with TEN who underwent resection from 2006-2019. Survival rates were assessed using the Kaplan-Meier method. Univariable and multivariable analyses were performed using the log-rank test and Cox proportional hazards model. A total of 100 patients were analyzed (51 females, median age 58 years). Thymoma was the most common histology (n = 92), followed by thymic carcinoma (n = 5), and thymic NET (neuroendocrine tumor) (n = 3). Stage II (Masaoka) tumours were most common (n = 51), followed by stage I (n = 27). WHO B2/B3 was the most prominent histological subtype (n = 34). Complete resection (R0) was achieved in 91 patients: 86/92 thymoma, 4/5 thymic carcinoma and 1/3 NET. The most common treatment modality was surgery alone in 72 patients, followed by surgery and radiation therapy in 24, and adjuvant chemoradiotherapy in 3 patients. Only one patient with thymic carcinoma received neoadjuvant chemotherapy. The 10-year overall and disease-free survival rates were 86.6% and 83.9%, respectively. Recurrence was most common in NETs (3/3). Risk factors for recurrence identified on multivariable analyses were: R1/2 resection (HR 9.30, 95%CI 1.82-36.1), TEN subtype (HR 8.08, 95%CI 1.24-34.6), and presence of lymphovascular invasion (LVI) (HR 9.56, 95%CI 2.56-25.8). Complete resection remains critical in patients with TEN. Incomplete resection, high-risk histology and LVI highlight the need for effective adjuvant modalities. Given the rarity of these diseases, emphasis must be placed on collaborative research conducted on TEN.